Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study. - 2021
Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study.
[en] OBJECTIVE: A subset of Crohn's disease (CD) patients experiences mid/long-term remission after infliximab withdrawal. Biomarkers are needed to identify those patients. DESIGN: New biomarkers of relapse were searched in the baseline serum of CD patients stopping infliximab when they were under combined therapy (antimetabolite and infliximab) and stable clinical remission (diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressors cohort, n=102). From shotgun proteomics experiment (discovery step), biomarker candidates were identified and further targeted by selected reaction monitoring (verification step). The dataset was stratified to search for markers of short-term (<6 months) or mid/long-term relapse (>6 months). The risk of relapse and the predicting capacity associated with biomarker candidates were evaluated using univariate Cox model and log-rank statistic, respectively. To test their complementary predicting capacity, biomarker candidates were systematically combined in pairs. RESULTS: Distinct biomarker candidates were associated with the risk (HR) of short-term (15 proteins, 2.9
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Pierre, Nicolas ; Université de Liège - ULiège > I3-Translational gastroenterology
De Pauw, Edwin ; Université de Liège - ULiège > Département de chimie (sciences) > Chimie analytique inorganique
Bouhnik, Yoram
Laharie, David
Colombel, Jean-Frédéric
Meuwis, Marie-Alice ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Language :
English
Title :
Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study.
Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the accent I randomised trial. Lancet 2002;359:1541-9.
Costa J, Magro F, Caldeira D, et al. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013;19:2098-110.
Louis E. Stopping biologics in IBD-What is the evidence? Inflamm Bowel Dis 2018;24:725-31.
Louis E, Belaiche J, Reenaers C. Anti-Tnf and Crohn's disease: when should we stop? Curr Drug Targets 2010;11:148-51.
Pittet V, Froehlich F, Maillard MH, et al. When do we Dare to stop biological or immunomodulatory therapy for Crohn's disease? results of a multidisciplinary European expert panel. J Crohns Colitis 2013;7:820-6.
Cottone M, Criscuoli V. Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol 2011;4:227-38.
Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517-24.
Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81.
Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012;143:390-9.
Karmiris K, Paintaud G, Noman M, et al. Influence of Trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40.
Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013;108:40-7.
Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009;30:265-74.
Bolin K, Hertervig E, Louis E. The cost-effectiveness of biological therapy cycles in the management of Crohn's disease. J Crohns Colitis 2019;13:1323-33.
van der Valk ME, Mangen M-JJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF therapy: results from the coin study. Gut 2014;63:72-9.
Torres J, Boyapati RK, Kennedy NA, et al. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology 2015;149:1716-30.
Consigny Y, Modigliani R, Colombel J-F, et al. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 2006;12:551-7.
Molander P, Färkkilä M, Ristimäki A, et al. Does fecal calprotectin predict short-term relapse after stopping TNF-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis 2015;9:33-40.
Chapman TP, Gomes CF, Louis E, et al. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2020;5:63-79.
Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-83.
Louis E, Mary J-Y, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63-70.
Meuwis M-A, Vernier-Massouille G, Grimaud JC, et al. Serum calprotectin as a biomarker for Crohn's disease. J Crohns Colitis 2013;7:e678-83.
de Suray N, Salleron J, Vernier-Massouille G, et al. 864 close monitoring of CRP and fecal calprotectin is able to predict clinical relapse in patients with Crohn's disease in remission after infliximab withdrawal. A Sub-Analysis of the Stori study. Gastroenterology 2012;142:S-149.
Davidson-Pilon C, Kalderstam J, Jacobson N. CamDavidsonPilon/lifelines: v0.24.8, 2019.
Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009;27:633-41.
Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 2012;9:555-66.
Geboes K. Histopathology of Crohn ' S disease and ulcerative colitis. Inflamm Bowel Dis 2003;18:255-76.
Zhou GX, Liu ZJ. Potential roles of neutrophils in regulating intestinal mucosal inflammation of inflammatory bowel disease. J Dig Dis 2017;18:495-503.
Mooiweer E, Severs M, Schipper MEI, et al. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis 2015;9:50-5.
Brookes MJ, Whitehead S, Gaya DR, et al. Practical guidance on the use of faecal calprotectin. Frontline Gastroenterol 2018;9:87-91.
Louis E. Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice. J Crohns Colitis 2015;9:1-3.
Buisson A, Gonzalez F, Poullenot F, et al. Comparative acceptability and perceived clinical utility of monitoring tools: a nationwide survey of patients with inflammatory bowel disease. Inflamm Bowel Dis 2017;23:1425-33.
Liverani E, Scaioli E, Digby RJ, et al. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol 2016;22:1017-33.
Novak G, Parker CE, Pai RK, et al. Histologic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev 2017;7:CD012351.
Brignola C, Campieri M, Bazzocchi G, et al. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986;91:1490-4.
Marks DJB, Rahman FZ, Sewell GW, et al. Crohn's disease: an immune deficiency state. Clin Rev Allergy Immunol 2010;38:20-31.
Kett K, Brandtzaeg P, Fausa O. J-Chain expression is more prominent in immunoglobulin A2 than in immunoglobulin A1 colonic immunocytes and is decreased in both subclasses associated with inflammatory bowel disease. Gastroenterology 1988;94:1419-25.
Johansen FE, Braathen R, Brandtzaeg P. Role of J chain in secretory immunoglobulin formation. Scand J Immunol 2000;52:240-8.
Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8.
Nguyen TMB, Subramanian IV, Kelekar A, et al. Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells. Blood 2007;109:4793-802.
Poon IKH, Patel KK, Davis DS, et al. Histidine-rich glycoprotein: the Swiss army knife of mammalian plasma. Blood 2011;117:2093-101.
Alkim C, Alkim H, Koksal AR, et al. Angiogenesis in inflammatory bowel disease. Int J Inflam 2015;2015:1-10.
Imhann F, Vich Vila A, Bonder MJ, et al. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut 2018;67:108-19.
Carr SA, Abbatiello SE, Ackermann BL, et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics 2014;13:907-17.
